Epinephrine Bitartrate: Non-Selective Adrenergic Agonist for Cardiovascular and Neurobiology Research

Executive Summary: (-)-Epinephrine (+)-bitartrate is a non-selective adrenergic receptor agonist targeting α₁, α₂, β₁, β₂, and β₃ subtypes, with EC₅₀ values of 5–10 nM in validated cell-based assays (APExBIO). It is used at concentrations of 1 nM–10 μM in vitro and 0.15–0.5 mg IM in clinical and animal studies, providing reproducible outcomes for vasoconstriction, bronchodilation, and heart rate modulation (See et al., 2023). The compound is highly soluble in water (≥22.9 mg/mL) and DMSO (≥16.66 mg/mL) but insoluble in ethanol. Storage at -20°C ensures chemical stability, and immediate use of solutions is recommended to prevent degradation. Overdose can induce arrhythmias; use is contraindicated in pheochromocytoma and hyperthyroidism (APExBIO).

Biological Rationale

Epinephrine Bitartrate (L-Epinephrine Bitartrate, Adrenaline Bitartrate) is an endogenous catecholamine and a potent non-selective adrenergic receptor agonist. It mediates critical physiological responses of the sympathetic nervous system, including vasoconstriction, elevation of blood pressure, increased heart rate, and bronchodilation (APExBIO). The compound’s broad receptor activation enables its use in cardiovascular disease research, neurobiology studies, and acute intervention models. Its defined pharmacodynamics and solubility profile facilitate reproducibility and precision in experimental design. Epinephrine Bitartrate is employed to dissect adrenergic signaling pathways, understand pathophysiological mechanisms in shock and asthma, and benchmark new vasopressor agents.

Mechanism of Action of (-)-Epinephrine (+)-bitartrate

(-)-Epinephrine (+)-bitartrate activates both α and β adrenergic receptors. It binds α₁ and α₂ subtypes (EC₅₀ ≈ 5 nM for α₁), leading to vasoconstriction and increased peripheral resistance. β₁ receptor activation (EC₅₀ ≈ 10 nM) increases cardiac contractility and heart rate. β₂ activation (EC₅₀ ≈ 8 nM) induces bronchodilation and smooth muscle relaxation. The compound also acts on β₃ receptors, modulating metabolic responses. These effects collectively recapitulate the physiological fight-or-flight response. The non-selective profile is essential for modeling multi-receptor adrenergic signaling in vitro and in vivo. Rapid onset and short half-life make it suitable for acute assays and interventions (APExBIO).

Evidence & Benchmarks

• Non-selective adrenergic receptor activation demonstrated at EC₅₀ ≈ 5–10 nM in cell-based assays (APExBIO).
• Clinically validated for intramuscular (0.3–0.5 mg adult, 0.01 mg/kg pediatric) and intranasal (2–20 mg canine) administration, providing reliable acute rescue in anaphylactic shock (APExBIO).
• Solubility benchmarked at ≥22.9 mg/mL in water and ≥16.66 mg/mL in DMSO, facilitating high-concentration stock solutions (APExBIO).
• Pharmacodynamic studies confirm blood pressure elevation and heart rate increase in animal models, supporting translational relevance (See et al., 2023).
• Storage at -20°C and immediate use of solutions are necessary to maintain potency and prevent oxidative degradation (APExBIO).

For a broader comparison of purity and assay reproducibility, see Epinephrine Bitartrate: High-Purity Adrenergic Receptor Agonist—this article extends those findings with updated in vivo benchmarks and current conversion ratios for translational studies.

Applications, Limits & Misconceptions

Epinephrine Bitartrate is essential for:

• Cell signaling assays requiring defined adrenergic receptor activation (Optimizing Cell Assays with (-)-Epinephrine (+)-bitartrate; this guide clarifies concentration ranges and solution handling for reproducibility).
• Translational animal models in cardiovascular disease and acute bronchial asthma (See et al., 2023).
• Adjuvant use in local anesthesia to prolong effect and reduce surgical bleeding (APExBIO).
• Emergency treatment of anaphylactic shock and acute asthma in both adult and pediatric populations.

However, its non-selective action can confound experiments targeting single adrenergic subtypes. Overdose risks include arrhythmia and severe hypertension. Contraindications are strict for patients with pheochromocytoma or hyperthyroidism.

Common Pitfalls or Misconceptions

• Misconception: Epinephrine Bitartrate is selective for β₂ receptors.
  Fact: It is non-selective and activates α and all β subtypes.
• Pitfall: Using ethanol as a solvent.
  Fact: Epinephrine Bitartrate is insoluble in ethanol; use water or DMSO instead.
• Misconception: Solutions are stable at room temperature.
  Fact: Solutions should be used immediately and stored at -20°C to prevent degradation.
• Pitfall: Generalizing animal dose findings to all species.
  Fact: Dosing is species-specific; follow validated protocols (e.g., 0.15–0.3 mg IM in canine models).
• Misconception: Safe for all patient populations.
  Fact: Contraindicated in pheochromocytoma and hyperthyroidism due to risk of hypertensive crisis.

Workflow Integration & Parameters

For in vitro assays, prepare fresh stock solutions in water or DMSO (≥22.9 mg/mL and ≥16.66 mg/mL, respectively). Use working concentrations of 1 nM–10 μM for cell function analysis. For in vivo studies, administer intramuscularly at 0.15–0.5 mg for adults or 0.01 mg/kg for pediatric subjects. In canines, intranasal doses range from 2–20 mg. All solutions should be stored at -20°C before use and protected from light. Monitor for potential adverse effects such as palpitations or arrhythmias. For detailed protocol guidance, see the product page (SKU B1358) and Epinephrine Bitartrate: Adrenergic Receptor Agonist for Cardiovascular Research—this article updates optimal dosing and storage recommendations for contemporary workflows.

Conclusion & Outlook

Epinephrine Bitartrate remains a cornerstone reagent for adrenergic receptor pharmacology, cardiovascular disease research, and emergency therapy modeling. Its well-characterized receptor profile, robust solubility, and validated dosing parameters ensure consistency in research and clinical applications. APExBIO supplies high-purity (-)-Epinephrine (+)-bitartrate (B1358), supporting rigorous scientific investigation. Ongoing studies will further refine its translational impact and facilitate cross-study standardization using norepinephrine equivalents (See et al., 2023). For advanced insights on mechanistic nuances and experimental design, see (-)-Epinephrine (+)-bitartrate: Advanced Insights—this resource is complemented by the present article's current clinical and in vivo benchmarks.